Metagenomi to Present at TD Cowen's 45th Annual Health Care Conference
Metagenomi (Nasdaq: MGX), a precision genetic medicines company, has announced that CEO and founder Brian C. Thomas, PhD, will participate in a fireside chat at TD Cowen's 45th Annual Health Care Conference on March 5, 2025, from 1:10-1:40 p.m. ET in Boston. The company will also host one-on-one investor meetings during the conference.
Metagenomi leverages an AI-driven metagenomics platform to develop curative therapeutics. The company's comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems. By studying genetic material from natural environments, Metagenomi has unlocked four billion years of microbial evolution to discover novel editing tools capable of correcting genetic mutations throughout the genome.
A live webcast of the presentation will be available on the company's investor relations website, with a replay available for a time.
Metagenomi (Nasdaq: MGX), un'azienda di medicina genetica di precisione, ha annunciato che il CEO e fondatore Brian C. Thomas, PhD, parteciperà a un incontro informale al 45° Annual Health Care Conference di TD Cowen il 5 marzo 2025, dalle 13:10 alle 13:40 ET a Boston. L'azienda ospiterà anche incontri individuali con gli investitori durante la conferenza.
Metagenomi sfrutta una piattaforma di metagenomica guidata dall'IA per sviluppare terapie curative. L'ampia cassetta degli attrezzi per la modifica del genoma dell'azienda include nucleasi programmabili, editori di basi e sistemi di integrazione mediati da RNA e DNA. Studiando il materiale genetico proveniente da ambienti naturali, Metagenomi ha sbloccato quattro miliardi di anni di evoluzione microbica per scoprire nuovi strumenti di editing in grado di correggere mutazioni genetiche in tutto il genoma.
Una trasmissione in diretta della presentazione sarà disponibile sul sito web delle relazioni con gli investitori dell'azienda, con una registrazione disponibile per un tempo.
Metagenomi (Nasdaq: MGX), una empresa de medicamentos genéticos de precisión, ha anunciado que el CEO y fundador Brian C. Thomas, PhD, participará en una charla informal en la 45ª Conferencia Anual de Salud de TD Cowen el 5 de marzo de 2025, de 1:10 a 1:40 p.m. ET en Boston. La empresa también organizará reuniones individuales con inversionistas durante la conferencia.
Metagenomi utiliza una plataforma de metagenómica impulsada por IA para desarrollar terapias curativas. El completo conjunto de herramientas para la edición del genoma de la empresa incluye nucleasas programables, editores de bases y sistemas de integración mediada por ARN y ADN. Al estudiar material genético de entornos naturales, Metagenomi ha desbloqueado cuatro mil millones de años de evolución microbiana para descubrir nuevas herramientas de edición capaces de corregir mutaciones genéticas en todo el genoma.
Una transmisión en vivo de la presentación estará disponible en el sitio web de relaciones con inversionistas de la empresa, con una repetición disponible por un tiempo.
메타제노미(Metagenomi) (Nasdaq: MGX)는 정밀 유전자 치료제 회사로, CEO 겸 창립자인 Brian C. Thomas 박사가 TD Cowen의 제45회 연례 의료 컨퍼런스에 참여하여 2025년 3월 5일 오후 1시 10분부터 1시 40분(ET)까지 보스턴에서 대담을 진행한다고 발표했습니다. 회사는 또한 회의 기간 동안 개별 투자자 미팅을 주최할 예정입니다.
메타제노미는 AI 기반 메타게놈 플랫폼을 활용하여 치료제를 개발합니다. 이 회사의 포괄적인 유전자 편집 툴킷에는 프로그래밍 가능한 뉴클레이스, 기초 편집기, RNA 및 DNA 매개 통합 시스템이 포함됩니다. 자연 환경에서 유전 물질을 연구함으로써 메타제노미는 40억 년의 미생물 진화를 통해 유전자 변이를 수정할 수 있는 새로운 편집 도구를 발견하였습니다.
발표의 라이브 웹캐스트는 회사의 투자자 관계 웹사이트에서 확인할 수 있으며, 일정 시간 동안 재생도 가능합니다.
Metagenomi (Nasdaq: MGX), une entreprise de médicaments génétiques de précision, a annoncé que le PDG et fondateur Brian C. Thomas, PhD, participera à une discussion informelle lors de la 45ème Conférence Annuelle sur la Santé de TD Cowen le 5 mars 2025, de 13h10 à 13h40 ET à Boston. L'entreprise organisera également des réunions individuelles avec des investisseurs durant la conférence.
Metagenomi utilise une plateforme de métagénomique pilotée par IA pour développer des thérapies curatives. L'arsenal complet d'édition du génome de l'entreprise comprend des nucléases programmables, des éditeurs de bases et des systèmes d'intégration médiés par ARN et ADN. En étudiant le matériel génétique provenant d'environnements naturels, Metagenomi a libéré quatre milliards d'années d'évolution microbienne pour découvrir de nouveaux outils d'édition capables de corriger des mutations génétiques dans tout le génome.
Une diffusion en direct de la présentation sera disponible sur le site web des relations investisseurs de l'entreprise, avec une rediffusion disponible pendant un certain temps.
Metagenomi (Nasdaq: MGX), ein Unternehmen für präzise genetische Medizin, hat angekündigt, dass der CEO und Gründer Brian C. Thomas, PhD, am 45. jährlichen Gesundheitskonferenz von TD Cowen am 5. März 2025 von 13:10 bis 13:40 Uhr ET in Boston an einem Fireside-Chat teilnehmen wird. Das Unternehmen wird während der Konferenz auch Einzelgespräche mit Investoren anbieten.
Metagenomi nutzt eine KI-gesteuerte Metagenomik-Plattform, um kurative Therapeutika zu entwickeln. Das umfassende Werkzeugset zur Genom-Editierung des Unternehmens umfasst programmierbare Nucleases, Basiseditoren und RNA- sowie DNA-vermittelte Integrationssysteme. Durch die Untersuchung genetischen Materials aus natürlichen Umgebungen hat Metagenomi vier Milliarden Jahre mikrobielle Evolution entschlüsselt, um neuartige Editing-Tools zu entdecken, die in der Lage sind, genetische Mutationen im gesamten Genom zu korrigieren.
Ein Live-Stream der Präsentation wird auf der Website der Investor-Relations des Unternehmens verfügbar sein, wobei eine Wiederholung für eine Zeitspanne verfügbar sein wird.
- None.
- None.
EMERYVILLE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that Brian C. Thomas, PhD, CEO and founder of Metagenomi, will participate in a fireside chat at TD Cowen's 45th Annual Health Care Conference on Wednesday, March 5, 2025, from 1:10-1:40 p.m. ET in Boston. The company will host one-on-one investor meetings at the conference.
A live webcast will be available in the investor section of the company's website at https://ir.metagenomi.co/ and a replay will be available for a limited time at the same address.
About Metagenomi
Metagenomi is a precision genetic medicines company committed to developing curative therapeutics for patients using its AI-driven metagenomics platform. Metagenomi is harnessing the power of metagenomics, the study of genetic material recovered from the natural environment, to unlock four billion years of microbial evolution to discover and develop a suite of novel editing tools capable of correcting any type of genetic mutation found anywhere in the genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat associated transposases (CAST)). Metagenomi believes its proprietary, modular toolbox positions the company to access the entire genome and select the optimal tool to unlock the full potential of genome editing for patients. For more information, please visit https://metagenomi.co.
Cautionary Note Regarding Forward‐Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions, include, but are not limited to, any statements relating to our growth strategy and product development programs, including the timing of and our ability to conduct IND-enabling studies, make regulatory filings such as INDs, statements concerning the potential of therapies and product candidates, and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in “Risk Factors,” in our most recent Form 10-K and our most recent 10-Qs on file with the Securities and Exchange Commission. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Contact:
IR@metagenomi.co
FAQ
When and where will Metagenomi (MGX) present at TD Cowen's Healthcare Conference?
What genome editing tools does Metagenomi (MGX) currently have in its toolbox?
How can investors access Metagenomi's (MGX) TD Cowen conference presentation?
What is unique about Metagenomi's (MGX) approach to genetic medicine development?
Will Metagenomi (MGX) offer individual investor meetings at the TD Cowen conference?
